Management of cardiovascular health in prostate cancer patients with androgen deprivation therapy
10.3760/cma.j.issn.1000-6702.2022.11.102
- VernacularTitle:前列腺癌患者雄激素剥夺治疗过程中的心血管疾病管理
- Author:
Yiqian CHEN
1
;
Weiyu ZHANG
;
Xiaodan LI
;
Tao XU
Author Information
1. 北京大学人民医院泌尿外科，北京 100044
- Keywords:
Prostatic neoplasms;
Carcinoma;
Androgen deprivation therapy;
Cardiovascular disease;
Management
- From:
Chinese Journal of Urology
2022;43(11):873-876
- CountryChina
- Language:Chinese
-
Abstract:
Androgen deprivation therapy is one of the main treatments for prostate cancer patients. In recent years, many studies have revealed that androgen deprivation therapy increases the risk of cardiovascular disease, which leads to the cause of death alongside tumor-related deaths. The mechanism may be related to the elevation of testosterone levels, follicle-stimulating hormone levels and unstable atherosclerotic plaque. Standardized cardiovascular disease management in this population is a key issue to improve survival and prognosis. This paper summarizes a management plan covering 5 areas, including history collecting and data examination, assessment, referral, health education, and regimen selection.
